Even though this is a short week, the stock market has been on fire and surging at the start. It’s not just blue-chip stocks that are displaying the biggest moves. Penny stocks have been displaying strong growth due to positive sentiment circling the country. This positive sentiment is coming from the idea that the economy could be reopening in the short-term. Even though a few specific sectors are on the skids, several others are cruising along.
Can this last? That’s the $10,000 question. Economic data will be abound moving forward and that could shift things significantly. Even though the stock market may move up and down overall, for the most part penny stocks will move to their own tune. To flesh it out, this means that even when the overall market could be declining, penny stocks may be soaring.
Here are a handful of questions you should ask yourself right now. Are you watching for penny stocks with a ton of volume right now? Are you looking for stocks with low floats? Is news important to you? Are you scanning social media along with press release outlets? Could chart patterns be your thing? The point is, there are several things to be watching right now that could put a stock on your buy and/or sell list. Make sure you’re ready to roll.
Your No. 1 Top Penny Stock To Watch Today: Safe-T Group Ltd.
Safe-T Group Ltd. (Nasdaq, TASE: SFET) is a provider of Zero Trust Access solutions which mitigate attacks on enterprises’ business-critical services and sensitive data, while ensuring uninterrupted business continuity. Safe-T’s cloud and on-premises solutions ensure that an organization’s access use cases, whether into the organization or from the organization out to the internet, are secured according to the “validate first, access later” philosophy of Zero Trust. This means that no one is trusted by default from inside or outside the network, and verification is required from everyone trying to gain access to resources on the network or in the cloud.
Safe-T® Group Ltd. today announced its financial results for the three-month period ended March 31, 2020.
Revenues totaled $1,088,000, an increase of 155% compared to $427,000 in the three-month period ended March 31, 2019.
The Company’s cash balance as of March 31, 2020 was $2,870,000.
Shachar Daniel, Chief Executive Officer, commented on the results: “We are pleased with our continuous improvement. The increase in revenue coupled with the reduction in our overall expenses, resulted in a significantly improved bottom line. We embarked on an expenditure streamlining plan a few quarters ago and we are proud to see that it has proved itself over time, with a significant decrease in all operational expense metrics without compromising the service to our customers or our ability to achieve revenue growth. In April 2020, our balance sheet was substantially strengthened with gross proceeds of more than $9 million raised through private and public equity offerings, and by the retirement in full of our debenture debt.”
Your No. 2 Top Penny Stock To Watch Today: Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals (Nasdaq: ZYNE) is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.
Zynerba Pharmaceuticals, Inc. today announced positive top line results from the exploratory, open label Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder) trial.
The trial was designed to assess the safety, tolerability and efficacy of Zygel™ in pediatric and adolescent patients with autism spectrum disorder (ASD). Zygel was administered to patients with moderate-to-severe symptoms of ASD as add-on therapy to their standard of care utilizing a variety of efficacy assessments. Key findings from the trial disclosed today include:
All five subscales of the Aberrant Behavior Checklist – Community (ABC-C) as well as the Parent Rated Anxiety Scale – Autism Spectrum Disorder (PRAS-ASD) showed both statistically significant and clinically meaningful improvements at 14 weeks of treatment from baseline;
The results observed in other efficacy outcome measures, including Clinical Global Impressions – Improvement scale (CGI-I), support the subscale results observed in the ABC-C;
Zygel was well tolerated in this trial with no serious or severe adverse events reported.
“We are very encouraged by the compelling top line results of the BRIGHT trial and we expect to meet with the FDA to discuss the clinical pathway for developing Zygel for the treatment of behavioral symptoms of ASD in the second half of this year,” said Armando Anido, Zynerba’s Chairman and Chief Executive Officer. “Our goal is to develop Zygel for patients suffering from debilitating neuropsychiatric disorders including ASD, Fragile X syndrome, 22q and DEE. I want to thank the patients, families, physicians, clinical staff, and the Zynerba team for their support of this key study in ASD.”
Your No. 3 Top Penny Stock To Watch Today: Greenpro Capital Corp.
Headquartered in Hong Kong with strategic offices across Asia, Greenpro Capital Corp. (NASDAQ:GRNQ) is a multinational conglomerate with a diversified business portfolio. With 30 years of experience in various industries, Greenpro has been assisting and supporting businesses and High-Net-Worth-Individuals to capitalize and securitize their value on a global scale through the provision of cross-border business solutions and accounting outsourcing services to small and medium-sized businesses located in Asia. The comprehensive range of cross-border business services include, but are not limited to, trust and wealth management, listing advisory services, transaction services, cross-border business solutions, record management services, accounting outsourcing services and tax advisory services.
Greenpro Capital Corp. recently announced that the Company has entered into a non-binding Letter of Intent with First Bullion Holdings Inc. and its subsidiaries (“First Bullion”) and with the shareholder of First Bullion (the “Seller”) to acquire an 18% equity interest of First Bullion. First Bullion is in the business of banking, payment gateway, credit cards, debit cards, money lending, crypto trading and securities token offering (“FB Services”) and with corporate offices in the Philippines and Hong Kong.
This potential acquisition will enhance and strengthen the business of Greenpro’s services comprising company formation, trust and asset protection, family office, financial planning and management, fund management and asset management, which will complement those services offered by First Bullion. The partnership will complement the services of Greenpro and First Bullion where clients will be crossed referred to each other and to assist our mutual international clients from around the world more efficiently and effectively with a higher standard of quality services.